A5036014237- Myasthenia Gravis and Thymoma
- Peripheral Neuropathies and Disorders
- T-cell and B-cell Immunology
- Antifungal resistance and susceptibility
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- Parkinson's Disease and Spinal Disorders
- Pituitary Gland Disorders and Treatments
- Cancer Treatment and Pharmacology
- Adrenal Hormones and Disorders
- RNA modifications and cancer
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Psoriasis: Treatment and Pathogenesis
- Genetics and Neurodevelopmental Disorders
- CAR-T cell therapy research
- Lymphatic System and Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Protein Tyrosine Phosphatases
- Chemokine receptors and signaling
- Adenosine and Purinergic Signaling
- Immunotherapy and Immune Responses
- Cholinesterase and Neurodegenerative Diseases
- Single-cell and spatial transcriptomics
- Neuroblastoma Research and Treatments
Institut de Myologie
2014-2025
Inserm
2016-2025
Sorbonne Université
2014-2025
Centre de Recherche en Myologie
2016-2025
John Wiley & Sons (United States)
2023
Hudson Institute
2023
Liechtenstein Institute
2023
Pitié-Salpêtrière Hospital
2018-2020
Astrophysique, Instrumentation et Modélisation
2012-2018
Centre National de la Recherche Scientifique
1994-2017
Myasthenia gravis (MG) is a chronic autoimmune disorder where autoantibodies target the nicotinic acetylcholine receptors (AChR+) in about 85% of cases, which thymus considered to play pathogenic role. As there are no reliable biomarkers monitor disease status MG, we analyzed circulating miRNAs sera MG patients find disease-specific miRNAs.Overall, 168 were serum samples from four AChR+ and healthy controls using Exiqon Focus miRNA polymerase chain reaction (PCR) Panel I + II. Specific...
The relationship between DNA methylation and gene expression is complex elusive. To further elucidate these relations, we performed an integrative analysis of the methylome transcriptome 4 circulating immune cell subsets (B cells, monocytes, CD4+, CD8+ T cells) from healthy females. Additionally, in light known sex bias prevalence several immune-mediated diseases, female datasets were compared with similar public available male data sets. Immune cell-specific differentially methylated...
Abstract Natural thymic T regulatory (tTreg) cells maintain tolerance to self-antigen. These are generated in the thymus, but how this generation occurs is still controversial. Furthermore, contribution of thymus epithelial process unclear, especially humans. Using an exceptional panel human samples, we demonstrated that medullary (mTECs) promote tTreg and favor their function. effects were mediated through soluble factors mTEC specific since other cell types had no such effect. By...
Myasthenia gravis (MG) is an autoimmune disease mediated by auto-antibodies that attack the nicotinic acetylcholine receptor (AChR). To elucidate molecular mechanisms underlying decrease in AChR levels at neuromuscular junction, we investigated regulation of expression analyzing mRNA two alpha subunit isoforms (P3A+ and P3A-) muscle samples from myasthenic patients relative to controls. We applied a quantitative method based on reverse transcription total RNA followed polymerase chain...
The thymus is frequently hyperplastic in young female myasthenia gravis (MG) patients presenting with anti‐acetylcholine receptor (AChR) antibodies. This thymic pathology characterized by the presence of ectopic germinal centers (GCs) containing B cells involved at least partially production pathogenic anti‐AChR Our recent studies have furthered our understanding mechanisms leading to GC formation thymus. First, we showed that CXCL13 and CCL21, chemokines formation, are overexpressed MG...
Autoimmune Myasthenia gravis (MG) is a chronic neuromuscular disease mainly due to antibodies against the acetylcholine receptor (AChR) at junction, leading invalidating muscle weaknesses. In early-onset MG, thymus effector organ and often characterized by B-cell infiltrations ectopic germinal center (GC) development. The microRNA miR-150-5p has been previously as biomarker in MG its increase serum of patients decrease after thymectomy, correlated with an improvement symptoms. Here, we...
Abstract Objective To identify novel genetic loci that predispose to early‐onset myasthenia gravis ( EOMG ) applying a two‐stage association study, exploration, and replication strategy. Methods Thirty‐four one confirmation loci, human leukocyte antigen HLA )‐ DRA , were selected as candidate genes by team members of groups involved in different research aspects MG . In the exploration step, these genotyped 384 matched controls significant difference allele frequency found eight genes. 1177...
Abstract Background Myasthenia gravis (MG) is a rare autoimmune disease mainly mediated by autoantibodies against the acetylcholine receptor (AChR) at neuromuscular junction. The thymus effector organ, and its removal alleviates symptoms of disease. In early-onset form MG, displays functional morphological abnormalities such as B cell infiltration leading to follicular hyperplasia, production AChR antibodies. Type-I interferon (IFN-I), especially IFN-β, orchestrator thymic changes observed...
Abstract In myasthenia gravis, the thymus is thought to be primary site of autosensitization. We investigated Vβ T‐cell repertoire at different intrathymic differentiation stages in 17 patients with gravis and 8 age‐matched control subjects by tricolor immunofluorescence, using a panel six anti‐Vβ antibodies. observed an increased expression Vβ5.1 Vβ8 subfamilies compared subjects. These increases were not only mature cells but also latest thymic precursors (double‐positive CD3 high), while...
Myasthenia gravis (MG) with anti–acetylcholine receptor (AChR) Abs is an autoimmune disease characterized by severe defects in immune regulation and thymic inflammation. Because mesenchymal stem cells (MSCs) display immunomodulatory features, we investigated whether how vitro–preconditioned human MSCs (cMSCs) could treat MG disease. We developed a new humanized preclinical model subcutaneously grafting fragments into immunodeficient NSG mice (NSG-MG model). Ninety percent of the animals...